Role of the C5a-C5a receptor axis in the inflammatory responses of the lungs after experimental polytrauma and hemorrhagic shock.
Adult
Animals
Aptamers, Peptide
/ pharmacology
Biomarkers
/ metabolism
Bronchoalveolar Lavage Fluid
Capillaries
/ pathology
Cell Line
Chemotaxis
/ drug effects
Complement C5a
/ metabolism
Disease Models, Animal
Humans
Inflammation
/ pathology
Lung
/ pathology
Male
Mice, Inbred C57BL
Mice, Knockout
Multiple Trauma
/ complications
Neutrophils
/ drug effects
Pulmonary Alveoli
/ pathology
Receptor, Anaphylatoxin C5a
/ deficiency
Shock, Hemorrhagic
/ complications
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 01 2021
25 01 2021
Historique:
received:
24
04
2020
accepted:
09
12
2020
entrez:
26
1
2021
pubmed:
27
1
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Singular blockade of C5a in experimental models of sepsis is known to confer protection by rescuing lethality and decreasing pro-inflammatory responses. However, the role of inhibiting C5a has not been evaluated in the context of sterile systemic inflammatory responses, like polytrauma and hemorrhagic shock (PT + HS). In our presented study, a novel and highly specific C5a L-aptamer, NoxD21, was used to block C5a activity in an experimental murine model of PT + HS. The aim of the study was to assess early modulation of inflammatory responses and lung damage 4 h after PT + HS induction. NoxD21-treated PT + HS mice displayed greater polymorphonuclear cell recruitment in the lung, increased pro-inflammatory cytokine levels in the bronchoalveolar lavage fluids (BALF) and reduced myeloperoxidase levels within the lung tissue. An in vitro model of the alveolar-capillary barrier was established to confirm these in vivo observations. Treatment with a polytrauma cocktail induced barrier damage only after 16 h, and NoxD21 treatment in vitro did not rescue this effect. Furthermore, to test the exact role of both the cognate receptors of C5a (C5aR1 and C5aR2), experimental PT + HS was induced in C5aR1 knockout (C5aR1 KO) and C5aR2 KO mice. Following 4 h of PT + HS, C5aR2 KO mice had significantly reduced IL-6 and IL-17 levels in the BALF without significant lung damage, and both, C5aR1 KO and C5aR2 KO PT + HS animals displayed reduced MPO levels within the lungs. In conclusion, the C5aR2 could be a putative driver of early local inflammatory responses in the lung after PT + HS.
Identifiants
pubmed: 33495506
doi: 10.1038/s41598-020-79607-1
pii: 10.1038/s41598-020-79607-1
pmc: PMC7835219
doi:
Substances chimiques
Aptamers, Peptide
0
Biomarkers
0
C5ar1 protein, mouse
0
C5ar2 protein, mouse
0
Receptor, Anaphylatoxin C5a
0
Complement C5a
80295-54-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2158Références
J Trauma Acute Care Surg. 2014 Mar;76(3):601-8; discussion 608-9
pubmed: 24553525
PLoS One. 2015 Jan 06;10(1):e0116772
pubmed: 25562599
Shock. 2018 Feb;49(2):154-163
pubmed: 28614141
Surgery. 1998 Oct;124(4):782-91; discussion 791-2
pubmed: 9781002
Oncol Res. 1998;10(2):75-84
pubmed: 9666515
ALTEX. 2016;33(3):251-60
pubmed: 26985677
Am J Respir Cell Mol Biol. 2017 Jul;57(1):18-27
pubmed: 28326803
Microvasc Res. 2002 Nov;64(3):384-97
pubmed: 12453433
Methods Mol Biol. 2012;844:115-24
pubmed: 22262438
PLoS One. 2010 Jun 08;5(6):e10982
pubmed: 20544027
J Immunol. 2006 Oct 1;177(7):4794-802
pubmed: 16982920
Sci Rep. 2017 Oct 25;7(1):14061
pubmed: 29070810
J Immunol. 2014 Nov 15;193(10):5099-107
pubmed: 25297874
J Trauma. 1999 Feb;46(2):224-33
pubmed: 10029025
Toxicol In Vitro. 2018 Mar;47:137-146
pubmed: 29155131
Shock. 2012 Apr;37(4):348-54
pubmed: 22258234
Nat Commun. 2015 Apr 22;6:6481
pubmed: 25901944
Nat Rev Nephrol. 2018 Jan;14(1):26-47
pubmed: 29199277
Lancet. 2016 Jun 11;387(10036):2383-401
pubmed: 27174305
Immunol Lett. 2019 May;209:45-52
pubmed: 30959077
Eur Respir J. 2008 Feb;31(2):252-60
pubmed: 18057061
J Clin Invest. 2012 Aug;122(8):2731-40
pubmed: 22850883
Eur Respir J. 2019 Nov 7;54(5):
pubmed: 31515398
FASEB J. 2013 Dec;27(12):5010-21
pubmed: 23982144
Cell Tissue Res. 2003 Jan;311(1):31-45
pubmed: 12483282
J Clin Invest. 2002 Jul;110(1):101-8
pubmed: 12093893
PLoS One. 2017 Sep 20;12(9):e0184956
pubmed: 28931049
Semin Immunol. 2016 Jun;28(3):278-84
pubmed: 27157701
Blood. 1991 Mar 1;77(5):1080-6
pubmed: 1995093
Shock. 2008 Jan;29(1):25-31
pubmed: 17621257
Virulence. 2019 Dec;10(1):677-694
pubmed: 31274379
Anal Chem. 2013 May 7;85(9):4247-50
pubmed: 23560702
Am Rev Respir Dis. 1986 Jul;134(1):141-5
pubmed: 3637065
Adv Exp Med Biol. 2012;946:147-59
pubmed: 21948367
Injury. 1998 Sep;29(7):509-14
pubmed: 10193492
J Biol Chem. 2005 Dec 2;280(48):39677-80
pubmed: 16204243
Blood. 2000 Oct 15;96(8):2784-92
pubmed: 11023512
Mol Ther. 2013 Dec;21(12):2236-46
pubmed: 23887360
J Gen Physiol. 2018 Feb 5;150(2):277-291
pubmed: 29282210
Nat Rev Immunol. 2004 Feb;4(2):133-42
pubmed: 15040586
J Immunol. 2017 Jun 15;198(12):4846-4854
pubmed: 28490576
Am J Respir Cell Mol Biol. 2016 Nov;55(5):657-666
pubmed: 27285858
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
Annu Rev Physiol. 2005;67:595-621
pubmed: 15709972
J Immunol. 2001 Jan 15;166(2):1193-9
pubmed: 11145701
J Crit Care. 2018 Apr;44:229-237
pubmed: 29175047
J Trauma. 2003 Jun;54(6):1127-30
pubmed: 12813333
Am J Respir Crit Care Med. 1994 Jul;150(1):113-22
pubmed: 8025736
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1579-84
pubmed: 9465058
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6390-E6399
pubmed: 28720697
FASEB J. 2001 Mar;15(3):568-70
pubmed: 11259369
Am J Respir Cell Mol Biol. 2001 Sep;25(3):306-15
pubmed: 11588008
FASEB J. 2002 Oct;16(12):1567-74
pubmed: 12374779
Nat Med. 2008 May;14(5):551-7
pubmed: 18454156
Int Immunopharmacol. 2018 Jan;54:221-225
pubmed: 29156357